Pfizer Inc. (NYSE:PFE) is a top low-cost stock to buy, with Q4 2025 earnings surpassing expectations at $17.6 billion in revenue and $0.66 EPS. Bernstein maintains a Market Perform rating and $30 price target, while emphasizing 2026 as a critical year for Pfizer’s strategic decisions and clinical development progress.

FDA grants Priority Review to Pfizer’s sBLA for HYMPAVZI (marstacimab) to expand indication for hemophilia A or B patients aged 6 and older, including pediatric patients aged 6 to 11 without inhibitors. Potential approval would make HYMPAVZI the first non-factor prophylactic treatment for children with hemophilia B in this age group.

Daiwa downgrades Pfizer (PFE) to Neutral post full-year 2025 earnings, citing greater upside potential in certain AI stocks. Pfizer remains a solid investment option, but investors seeking undervalued AI stocks can benefit from a free report on the best short-term AI stock.

Pfizer Inc. (NYSE:PFE) is a leading biopharmaceutical company with a focus on discovering, developing, and distributing innovative products globally. While Pfizer’s long-term valuation hinges on strategic investments and clinical milestones in 2026, the firm faces uncertainties in a transitional period despite strong financial results.

Read more at Yahoo Finance: Daiwa Downgrades Pfizer (PFE) to Neutral Following Full-Year 2025 Earnings